Brandon May

Researchers examined health disparities in the duration of asthma exacerbations in patients post-COVID-19.

A post hoc analysis of the QUEST trial assessed clinical remission in patients with moderate-to-severe asthma after 24 and 52 weeks of dupilumab treatment.

CHRONICLE trial findings offer a glimpse of the real-world outcomes of patients using benralizumab for severe asthma over a years’ time.

A prospective, single-center study examined the use of allergen immunotherapy for alleviating the burden of allergic rhinitis.

The phase 4 VESTIGE trial is using functional respiratory imaging to assess the effect of dupilumab on lung function and airway volume in asthma.

Research presented at CHEST 2021 assessed an alternative approach to predicting COPD exacerbations during the COVID-19 pandemic.

A NYC hospital study explored disease severity in Black individuals with COVID-19 pneumonia, using D-dimer as a surrogate marker.

Researchers evaluated the relationship between e-cigarettes and obstructive pulmonary diseases, taking into account age, gender, ethnicity, and body mass index.

NAVIGATOR trial results presented at CHEST 2021 show the effect of tezepelumab on peak expiratory flow rates in severe asthma.

A post-hoc analysis of the VENTURE trial evaluated whether baseline oral corticosteroid dosage affected the efficacy of dupilumab in improving severe asthma outcomes.